




Instance: composition-en-8ff5d67e0b7de732bda1082340f24212
InstanceOf: CompositionUvEpi
Title: "Composition for sotyktu Package Leaflet"
Description:  "Composition for sotyktu Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8ff5d67e0b7de732bda1082340f24212)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sotyktu"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What SOTYKTU is and what it is used for </li>
<li>What you need to know before you take SOTYKTU </li>
<li>How to take SOTYKTU </li>
<li>Possible side effects </li>
<li>How to store SOTYKTU </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sotyktu is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sotyktu is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What SOTYKTU is 
SOTYKTU contains the active substance deucravacitinib, which belongs to a group of medicines 
called tyrosine kinase 2 (TYK2) inhibitors that help to reduce inflammation associated with psoriasis. </p>
<p>What SOTYKTU is used for 
SOTYKTU is used to treat adults with moderate to severe  plaque psoriasis , an inflammatory 
condition affecting the skin, which can cause red, scaly, thick, itchy, painful patches on your skin and 
can also affect your scalp and nails, hands, and feet. </p>
<p>How SOTYKTU works 
SOTYKTU works by selectively blocking the activity of an enzyme called  TYK2  (tyrosine kinase 2) 
which is involved in the process of inflammation. By reducing the activity of this enzyme, SOTYKTU 
can help to control the inflammation associated with plaque psoriasis and thereby reduce the signs 
(skin dryness, cracking, scaling, shedding, or flaking, redness and bleeding) and can therefore help to 
reduce symptoms such as itching, pain, burning, stinging, and skin tightness of this condition. </p>
<p>SOTYKTU has also been shown to improve the quality of life in patients with psoriasis. This means 
that the impact of your condition on daily activities, relationships and other factors should be less than 
it was before. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sotyktu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sotyktu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take SOTYKTU 
* if you are allergic to deucravacitinib or any of the other ingredients of this medicine (listed in 
section 6). 
* if you have an infection, including active tuberculosis (TB) which your doctor thinks is 
important. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking SOTYKTU: 
* if you currently have an infection that does not go away or that keeps coming back 
* if you have or have ever had tuberculosis (TB) 
* if you have cancer, because your doctor will have to decide if you can still be given SOTYKTU 
* if you have heart problems or medical conditions that make you more likely to develop heart 
disease - it is not clear if SOTYKTU increases the risk of heart disease 
* if you have had or are at risk of blood clots in the veins of your legs (deep vein thrombosis) or 
lungs (pulmonary embolism). Tell your doctor if you get a painful swollen leg, chest pain, or 
shortness of breath as these can be signs of blood clots in the veins. It is not clear if SOTYKTU 
increases the risk of blood clots 
* if you have recently had or plan to have a vaccination. </p>
<p>If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before 
using SOTYKTU. </p>
<p>Children and adolescents 
SOTYKTU is not recommended for children and adolescents under 18 years of age because it has not 
been evaluated in this age group. </p>
<p>Other medicines and SOTYKTU 
Tell your doctor or pharmacist: 
* if you are taking, have recently taken or might take any other medicines 
* if you recently had or plan to have a vaccination. You should not be given certain types of 
vaccines (live vaccines) while using SOTYKTU. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine. This is because it is not known how this medicine 
will affect the baby. </p>
<p>Driving and using machines 
SOTYKTU is not expected to affect your ability to drive or use machines. </p>
<p>SOTYKTU contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>
<p>SOTYKTU contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sotyktu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sotyktu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is 6 mg taken every day. The tablet should be swallowed whole and can be 
taken either with or without food. Do not crush, cut, or chew the tablets. </p>
<p>Your doctor will decide for how long you need to use SOTYKTU. </p>
<p>If your condition has not improved after six months of treatment, talk to your doctor. </p>
<p>If you take more SOTYKTU than you should 
If you have taken more SOTYKTU than you should, talk to your doctor as soon as possible. You may 
get some of the side effects listed in section 4. If you forget to take SOTYKTU 
If you forgot to take SOTYKTU, just take the normal dose the next day. Do not take a double dose to 
make up for a forgotten tablet. </p>
<p>If you stop taking SOTYKTU 
Do not stop taking SOTYKTU without talking to your doctor first. If you stop treatment, symptoms of 
psoriasis may come back. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Very common (may affect more than 1 in 10 people) 
* upper respiratory tract (nose and throat) infections with symptoms such as sore throat and stuffy 
nose </p>
<p>Common (may affect up to 1 in 10 people) 
* viral infection of the mouth (such as cold sores) 
* an increase in the level of an enzyme in your blood called creatine phosphokinase (CPK) 
* sores in mouth 
* acne-like rashes 
* inflammation of hair follicles </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* shingles (herpes zoster) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, nurse, or pharmacist. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects, you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sotyktu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sotyktu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and carton after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not use this medicine if you notice the tablets are damaged or there are signs of tampering with the 
medicine packaging. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What SOTYKTU contains 
The active substance is deucravacitinib. Each film-coated tablet contains 6 mg of deucravacitinib. </p>
<p>The other ingredients are 
* tablet core: hypromellose acetate succinate, anhydrous lactose, microcrystalline cellulose, 
croscarmellose sodium, colloidal hydrated silica and magnesium stearate. 
* film-coating: polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, iron oxide red (E172) 
and iron oxide yellow (E172). </p>
<p>What SOTYKTU looks like and contents of the pack 
SOTYKTU is a pink, round, biconvex, film-coated tablet printed with  BMS 895 and  6 mg  on one 
side, in two lines, plain on the other side. </p>
<p>The film-coated tablets are provided in calendar or non-calendar blisters containing 7 or 14 tablets. 
Each pack contains 7, 14, 28 or 84 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Bristol-Myers Squibb Pharma EEIG 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIreland </p>
<p>Manufacturer 
Swords Laboratories Unlimited Company 
T/A Bristol-Myers Squibb Pharmaceutical Operations 
External Manufacturing 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIreland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing<br />
Authorisation Holder: </p>
<p>Belgique/Belgi /Belgien 
N.V. Bristol-Myers Squibb Belgium S.A. 
T l/Tel: + 32 2 352 76 medicalinfo.belgium@bms.com </p>
<p>Lietuva 
Swixx Biopharma UAB 
Tel: + 370 52 369medinfo.lithuania@swixxbiopharma.com </p>
<p>Swixx Biopharma EOOD 
Te .: + 359 2 4942 medinfo.bulgaria@swixxbiopharma.com </p>
<p>Luxembourg/Luxemburg 
N.V. Bristol-Myers Squibb Belgium S.A. 
T l/Tel: + 32 2 352 76 medicalinfo.belgium@bms.com </p>
<p>esk  republika 
Bristol-Myers Squibb spol. s r.o. 
Tel: + 420 221 016 medinfo.czech@bms.com </p>
<p>Magyarorsz g 
Bristol-Myers Squibb Kft. 
Tel.: + 36 1 301 9Medinfo.hungary@bms.com </p>
<p>Danmark 
Bristol-Myers Squibb Denmark 
Tlf: + 45 45 93 05 medinfo.denmark@bms.com </p>
<p>Malta 
A.M. Mangion Ltd 
Tel: + 356 23976pv@ammangion.com </p>
<p>Deutschland 
Bristol-Myers Squibb GmbH &amp; Co. KGaA 
Tel: 0800 0752002 (+ 49 89 121 42 350) 
medwiss.info@bms.com </p>
<p>Nederland 
Bristol-Myers Squibb B.V. 
Tel: + 31 (0)30 300 2medischeafdeling@bms.com </p>
<p>Eesti 
Swixx Biopharma O<br />
Tel: + 372 640 1medinfo.estonia@swixxbiopharma.com </p>
<p>Norge 
Bristol-Myers Squibb Norway Ltd. 
Tlf: + 47 67 55 53 medinfo.norway@bms.com </p>
<p>Bristol-Myers Squibb A.E. 
 : + 30 210 6074medinfo.greece@bms.com </p>
<p>sterreich 
Bristol-Myers Squibb GesmbH 
Tel: + 43 1 60 14 medinfo.austria@bms.com </p>
<p>Espa a 
Bristol-Myers Squibb, S.A. 
Tel: + 34 91 456 53 informacion.medica@bms.com </p>
<p>Polska 
Bristol-Myers Squibb Polska Sp. z o.o. 
Tel.: + 48 22 2606informacja.medyczna@bms.com </p>
<p>France 
Bristol-Myers Squibb SAS 
T l: + 33 (0)1 58 83 84 infomed@bms.com </p>
<p>Portugal 
Bristol-Myers Squibb Farmac utica Portuguesa, 
S.A. 
Tel: + 351 21 440 70 portugal.medinfo@bms.com </p>
<p>Hrvatska 
Swixx Biopharma d.o.o. 
Tel: + 385 1 2078 medinfo.croatia@swixxbiopharma.com </p>
<p>Rom nia 
Bristol-Myers Squibb Marketing Services S.R.L. 
Tel: + 40 (0)21 272 16 medinfo.romania@bms.com </p>
<p>Ireland 
Bristol-Myers Squibb Pharmaceuticals uc 
Tel: 1 800 749 749 (+ 353 (0)1 483 3625) 
medical.information@bms.com </p>
<p>Slovenija 
Swixx Biopharma d.o.o. 
Tel: + 386 1 2355 medinfo.slovenia@swixxbiopharma.com </p>
<p>sland 
Vistor hf. 
S mi: + 354 535 7vistor@vistor.is 
medical.information@bms.com </p>
<p>Slovensk  republika 
Swixx Biopharma s.r.o. 
Tel: + 421 2 20833 medinfo.slovakia@swixxbiopharma.com<br />
Italia 
Bristol-Myers Squibb S.r.l. 
Tel: + 39 06 50 39 medicalinformation.italia@bms.com </p>
<p>Suomi/Finland 
Oy Bristol-Myers Squibb (Finland) Ab 
Puh/Tel: + 358 9 251 21 medinfo.finland@bms.com </p>
<p>Bristol-Myers Squibb A.E. 
 :  800 92666 (+ 30 210 6074300) 
medinfo.greece@bms.com </p>
<p>Sverige 
Bristol-Myers Squibb Aktiebolag 
Tel: + 46 8 704 71 medinfo.sweden@bms.com </p>
<p>Latvija 
Swixx Biopharma SIA 
Tel: + 371 66164medinfo.latvia@swixxbiopharma.com </p>
<p>United Kingdom (Northern Ireland) 
Bristol-Myers Squibb Pharmaceutical Limited 
Tel: +44 (0)800 731 1medical.information@bms.com </p>
<p>This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-8ff5d67e0b7de732bda1082340f24212
InstanceOf: CompositionUvEpi
Title: "Composition for sotyktu Package Leaflet"
Description:  "Composition for sotyktu Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8ff5d67e0b7de732bda1082340f24212)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sotyktu"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage SOTYKTU </li>
<li>Sådan skal du tage SOTYKTU </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sotyktu is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sotyktu is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning 
SOTYKTU indeholder det aktive stof deucravacitinib, som tilhører en gruppe lægemidler, der kaldes 
tyrosinkinase 2-hæmmere (TYK2-hæmmere), der hjælper med at reducere betændelse i forbindelse 
med psoriasis. </p>
<p>Anvendelse 
SOTYKTU bruges til at behandle voksne patienter med moderat til svær "plaque psoriasis", en 
betændelsestilstand, der påvirker huden, som kan medføre røde, skællende, fortykkede, kløende, 
smertefulde områder på huden og også kan påvirke hovedbunden, neglene, hænderne og fødderne. </p>
<p>Hvordan SOTYKTU virker 
SOTYKTU virker ved selektivt at blokere aktiviteten af et enzym, der kaldes "TYK2" 
(tyrosinkinase 2), som er en del af betændelsesprocessen. Ved at reducere aktiviteten af dette enzym 
kan SOTYKTU være med til at kontrollere betændelsen i forbindelse med plaque psoriasis og dermed 
reducere tegn (tør hud, revner, afskalning, flagedannelse, rødme og blødning) og kan dermed være 
med til at reducere symptomer, såsom kløe, smerter, brændende fornemmelse, svie og stram hud, ved 
denne lidelse. </p>
<p>Det er desuden påvist, at SOTYKTU kan forbedre livskvaliteten hos patienter med psoriasis. Det 
betyder, at den påvirkning, som din sygdom har på dagligdags aktiviteter, relationer og andre faktorer, 
nok vil blive mindre end før. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sotyktu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sotyktu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke SOTYKTU </p>
<ul>
<li>
<p>hvis du er allergisk over for deucravacitinib eller et af de øvrige indholdsstoffer i SOTYKTU 
(angivet i afsnit 6). </p>
</li>
<li>
<p>hvis du har en infektion, herunder aktiv tuberkulose (TB), som din læge mener er vigtig. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager SOTYKTU: </p>
<ul>
<li>
<p>hvis du i øjeblikket har en infektion, som ikke forsvinder eller bliver ved med at komme tilbage </p>
</li>
<li>
<p>hvis du har eller nogensinde har haft tuberkulose (TB) </p>
</li>
<li>
<p>hvis du har kræft, da din læge så skal beslutte, om du stadig kan få SOTYKTU </p>
</li>
<li>
<p>hvis du har hjerteproblemer eller sygdomme, der gør det mere sandsynligt, at du udvikler 
hjertesygdomme - det vides ikke, om SOTYKTU øger risikoen for hjertesygdom </p>
</li>
<li>
<p>hvis du har haft eller har risiko for at få blodpropper i venerne i benene (dyb venetrombose) 
eller lungerne (lungeemboli). Fortæl det til lægen, hvis dit ben hæver op og gør ondt, eller hvis 
du får smerter i brystet eller åndenød, da dette kan være tegn på blodpropper i venerne. Det 
vides ikke, om SOTYKTU øger risikoen for blodpropper </p>
</li>
<li>
<p>hvis du er blevet vaccineret for nylig eller planlægger at blive det. </p>
</li>
</ul>
<p>Kontakt lægen, apotekspersonalet eller sygeplejersken, før du bruger SOTYKTU, hvis du er i tvivl 
om, hvorvidt noget af ovenstående gælder for dig. </p>
<p>Børn og unge 
SOTYKTU frarådes til børn og unge under 18 år, da det ikke er blevet undersøgt til denne 
aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med SOTYKTU 
Fortæl det altid til lægen eller apotekspersonalet: </p>
<ul>
<li>
<p>hvis du tager andre lægemidler, for nylig har taget andre lægemidler eller planlægger at tage 
andre lægemidler </p>
</li>
<li>
<p>hvis du er blevet vaccineret for nylig eller planlægger at blive det. Du må ikke få visse typer af 
vacciner (levende vacciner), mens du bruger SOTYKTU. </p>
</li>
</ul>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager dette lægemiddel. Det skyldes, at man ikke ved, hvordan dette 
lægemiddel vil påvirke barnet. </p>
<p>Trafik- og arbejdssikkerhed 
SOTYKTU forventes ikke at påvirke din evne til at køre bil eller betjene maskiner. </p>
<p>SOTYKTU indeholder lactose 
Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>
<p>SOTYKTU indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sotyktu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sotyktu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er 6 mg hver dag. Tabletten skal synkes hel og kan tages med eller uden mad. 
Tabletterne må ikke knuses, deles eller tygges. </p>
<p>Din læge vil beslutte, hvor længe du skal bruge SOTYKTU. </p>
<p>Kontakt lægen, hvis din tilstand ikke er blevet bedre efter seks måneders behandling. </p>
<p>Hvis du har taget for meget SOTYKTU 
Kontakt lægen hurtigst muligt, hvis du har taget for meget SOTYKTU. Det kan være, at du får nogle 
af de bivirkninger, der er anført i afsnit 4. Hvis du har glemt af tage SOTYKTU 
Hvis du har glemt at tage SOTYKTU, skal du blot tage din sædvanlige dosis næste dag. Du må ikke 
tage en dobbeltdosis som erstatning for den glemte tablet. </p>
<p>Hvis du holder op med at tage SOTYKTU 
Hold ikke op med at tage SOTYKTU uden først at tale med lægen. Hvis du stopper behandlingen, kan 
dine psoriasis-symptomer vende tilbage. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 personer) </p>
<ul>
<li>infektioner i øvre luftveje (næse og svælg) med symptomer såsom ondt i halsen og tilstoppet 
næse </li>
</ul>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>virusinfektion i munden (såsom forkølelsessår) </p>
</li>
<li>
<p>en stigning i niveauet af et enzym i blodet, der kaldes kreatinfosfokinase (CPK) </p>
</li>
<li>
<p>mundsår </p>
</li>
<li>
<p>akne-lignende udslæt </p>
</li>
<li>
<p>betændelse i hårsække </p>
</li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>helvedesild (herpes zoster) </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sotyktu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sotyktu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisterkortet og kartonen efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Brug ikke lægemidlet, hvis du bemærker, at tabletterne er gået i stykker, eller hvis der er tegn på, at 
pakningen har været åbnet af andre. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>SOTYKTU indeholder: 
Aktivt stof: deucravacitinib. Hver filmovertrukket tablet indeholder 6 mg deucravacitinib. </p>
<p>Øvrige indholdsstoffer: </p>
<ul>
<li>
<p>tabletkerne: hypromelloseacetatsuccinat, vandfri lactose, mikrokrystallinsk cellulose, 
croscarmellosenatrium, kolloidt hydreret silica og magnesiumstearat. </p>
</li>
<li>
<p>filmovertræk: polyvinylalkohol, titandioxid (E171), macrogol, talcum, rød jernoxid (E172) og 
gul jernoxid (E172). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
SOTYKTU er en lyserød, rund, bikonveks filmovertrukket tablet påtrykt "BMS 895" og "6 mg" på 
den ene side på to linjer og glat på den anden side. </p>
<p>De filmovertrukne tabletter fås i blisterkort med eller uden kalender indeholdende 7 eller 14 tabletter. 
Hver pakning indeholder 7, 14, 28 eller 84 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Bristol-Myers Squibb Pharma EEIG 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIrland </p>
<p>Fremstiller 
Swords Laboratories Unlimited Company 
T/A Bristol-Myers Squibb Pharmaceutical Operations 
External Manufacturing 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIrland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>Belgique/België/Belgien 
N.V. Bristol-Myers Squibb Belgium S.A. 
Tél/Tel: + 32 2 352 76 medicalinfo.belgium@bms.com </p>
<p>Lietuva 
Swixx Biopharma UAB 
Tel: + 370 52 369medinfo.lithuania@swixxbiopharma.com </p>
<p>България 
Swixx Biopharma EOOD 
Teл.: + 359 2 4942 medinfo.bulgaria@swixxbiopharma.com </p>
<p>Luxembourg/Luxemburg 
N.V. Bristol-Myers Squibb Belgium S.A. 
Tél/Tel: + 32 2 352 76 medicalinfo.belgium@bms.com </p>
<p>Česká republika 
Bristol-Myers Squibb spol. s r.o. 
Tel: + 420 221 016 medinfo.czech@bms.com </p>
<p>Magyarország 
Bristol-Myers Squibb Kft. 
Tel.: + 36 1 301 9Medinfo.hungary@bms.com </p>
<p>Danmark 
Bristol-Myers Squibb Denmark 
Tlf: + 45 45 93 05 medinfo.denmark@bms.com </p>
<p>Malta 
A.M. Mangion Ltd 
Tel: + 356 23976pv@ammangion.com </p>
<p>Deutschland 
Bristol-Myers Squibb GmbH &amp; Co. KGaA 
Tel: 0800 0752002 (+ 49 89 121 42 350) 
medwiss.info@bms.com </p>
<p>Nederland 
Bristol-Myers Squibb B.V. 
Tel: + 31 (0)30 300 2medischeafdeling@bms.com </p>
<p>Eesti 
Swixx Biopharma OÜ 
Tel: + 372 640 1medinfo.estonia@swixxbiopharma.com </p>
<p>Norge 
Bristol-Myers Squibb Norway AS 
Tlf: + 47 67 55 53 medinfo.norway@bms.com </p>
<p>Ελλάδα 
Bristol-Myers Squibb A.E. 
Τηλ: + 30 210 6074medinfo.greece@bms.com </p>
<p>Österreich 
Bristol-Myers Squibb GesmbH 
Tel: + 43 1 60 14 medinfo.austria@bms.com </p>
<p>España 
Bristol-Myers Squibb, S.A. 
Tel: + 34 91 456 53 informacion.medica@bms.com </p>
<p>Polska 
Bristol-Myers Squibb Polska Sp. z o.o. 
Tel.: + 48 22 2606informacja.medyczna@bms.com </p>
<p>France 
Bristol-Myers Squibb SAS 
Tél: + 33 (0)1 58 83 84 infomed@bms.com </p>
<p>Portugal 
Bristol-Myers Squibb Farmacêutica Portuguesa, 
S.A. 
Tel: + 351 21 440 70 portugal.medinfo@bms.com </p>
<p>Hrvatska 
Swixx Biopharma d.o.o. 
Tel: + 385 1 2078 medinfo.croatia@swixxbiopharma.com </p>
<p>România 
Bristol-Myers Squibb Marketing Services S.R.L. 
Tel: + 40 (0)21 272 16 medinfo.romania@bms.com </p>
<p>Ireland 
Bristol-Myers Squibb Pharmaceuticals uc 
Tel: 1 800 749 749 (+ 353 (0)1 483 3625) 
medical.information@bms.com </p>
<p>Slovenija 
Swixx Biopharma d.o.o. 
Tel: + 386 1 2355 medinfo.slovenia@swixxbiopharma.com </p>
<p>Ísland 
Vistor hf. 
Sími: + 354 535 7vistor@vistor.is 
medical.information@bms.com </p>
<p>Slovenská republika 
Swixx Biopharma s.r.o. 
Tel: + 421 2 20833 medinfo.slovakia@swixxbiopharma.com<br />
Italia 
Bristol-Myers Squibb S.r.l. 
Tel: + 39 06 50 39 medicalinformation.italia@bms.com </p>
<p>Suomi/Finland 
Oy Bristol-Myers Squibb (Finland) Ab 
Puh/Tel: + 358 9 251 21 medinfo.finland@bms.com </p>
<p>Κύπρος 
Bristol-Myers Squibb A.E. 
Τηλ:  800 92666 (+ 30 210 6074300) 
medinfo.greece@bms.com </p>
<p>Sverige 
Bristol-Myers Squibb Aktiebolag 
Tel: + 46 8 704 71 medinfo.sweden@bms.com </p>
<p>Latvija 
Swixx Biopharma SIA 
Tel: + 371 66164medinfo.latvia@swixxbiopharma.com </p>
<p>United Kingdom (Northern Ireland) 
Bristol-Myers Squibb Pharmaceutical Limited 
Tel: +44 (0)800 731 1medical.information@bms.com </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      



Instance: composition-pt-8ff5d67e0b7de732bda1082340f24212
InstanceOf: CompositionUvEpi
Title: "Composition for sotyktu Package Leaflet"
Description:  "Composition for sotyktu Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8ff5d67e0b7de732bda1082340f24212)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sotyktu"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #pt
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. FOLHETO INFORMATIVO"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. FOLHETO INFORMATIVO"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Folheto informativo: Informação para o utilizador"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Folheto informativo: Informação para o utilizador"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "O que contém este folheto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "O que contém este folheto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>O que contém este folheto: </p>
<ol>
<li>O que é SOTYKTU e para que é utilizado </li>
<li>O que precisa de saber antes de tomar SOTYKTU </li>
<li>Como tomar SOTYKTU </li>
<li>Efeitos indesejáveis possíveis </li>
<li>Como conservar SOTYKTU </li>
<li>Conteúdo da embalagem e outras informações </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. O que é sotyktu e para que é utilizado"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. O que é sotyktu e para que é utilizado"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>O que é SOTYKTU 
SOTYKTU contém a substância ativa deucravacitinib, que pertence a um grupo de medicamentos 
denominado inibidores da tirosina cinase 2 (TYK2) que ajudam a reduzir a inflamação associada à 
psoríase. </p>
<p>Para que é utilizado SOTYKTU 
SOTYKTU é utilizado para tratar adultos com “psoríase em placas" moderada a grave, uma condição 
inflamatória que afeta a pele e que pode provocar manchas vermelhas, escamosas, espessas, que 
provocam comichão e dolorosas na pele, e que também pode afetar o couro cabeludo, as unhas, as 
mãos e os pés. </p>
<p>Como funciona SOTYKTU 
SOTYKTU bloqueia de forma seletiva a atividade de uma enzima denominada “TYK2" (tirosina 
cinase 2) que está envolvida no processo de inflamação. Ao reduzir a atividade desta enzima, 
SOTYKTU pode ajudar a controlar a inflamação associada à psoríase em placas, reduzindo assim os 
sinais (pele seca, pele gretada, descamação da pele, vermelhidão e sangramento) e pode, por 
conseguinte, ajudar a reduzir os sintomas, tais como comichão, dor, ardor, sensação de picadas e pele 
repuxada, desta condição. </p>
<p>SOTYKTU também demonstrou melhorar a qualidade de vida dos doentes com psoríase. Isto significa 
que o impacto da sua condição em atividades diárias, relações e outros fatores deverá ser inferior ao 
que era anteriormente. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. O que precisa de saber antes de tomar sotyktu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. O que precisa de saber antes de tomar sotyktu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Não tome SOTYKTU </p>
<ul>
<li>
<p>se tem alergia ao deucravacitinib ou a qualquer outro componente deste medicamento 
(indicados na secção 6). </p>
</li>
<li>
<p>se tem uma infeção, incluindo tuberculose (TB) ativa, que o seu médico considere importante. </p>
</li>
</ul>
<p>Advertências e precauções 
Fale com o seu médico ou farmacêutico antes de tomar SOTYKTU: </p>
<ul>
<li>
<p>se tem atualmente uma infeção que não desaparece ou que é recorrente </p>
</li>
<li>
<p>se tem ou teve tuberculose (TB) </p>
</li>
<li>
<p>se tem cancro, porque o seu médico terá de decidir se pode na mesma iniciar o tratamento com 
SOTYKTU </p>
</li>
<li>
<p>se tem problemas cardíacos ou condições médicas que o tornam mais propenso a desenvolver 
doença cardíaca - não é claro se SOTYKTU aumenta o risco de doença cardíaca </p>
</li>
<li>
<p>se esteve ou está em risco de ter coágulos de sangue nas veias das pernas (trombose venosa 
profunda) ou nos pulmões (embolismo pulmonar). Informe o seu médico se ficar com uma 
perna inchada e com dor, se tiver dores no peito ou se ficar com falta de ar, pois estes podem ser 
sinais de coágulos de sangue nas veias. Não é claro se SOTYKTU aumenta o risco de coágulos 
de sangue </p>
</li>
<li>
<p>se recebeu recentemente ou planeia receber uma vacina. </p>
</li>
</ul>
<p>Caso tenha dúvidas sobre se alguma das situações acima descritas se aplica a si, fale com o seu 
médico, farmacêutico ou enfermeiro antes de tomar SOTYKTU. </p>
<p>Crianças e adolescentes 
SOTYKTU não é recomendado para crianças e adolescentes com menos de 18 anos, pois não foi 
avaliado para este grupo etário. </p>
<p>Outros medicamentos e SOTYKTU 
Informe o seu médico ou farmacêutico: </p>
<ul>
<li>
<p>se estiver a tomar, tiver tomado recentemente, ou se vier a tomar outros medicamentos </p>
</li>
<li>
<p>se tiver recebido recentemente ou planeia receber uma vacina. Não lhe devem ser administrados 
determinados tipos de vacinas (vacinas vivas) enquanto está a tomar SOTYKTU. </p>
</li>
</ul>
<p>Gravidez e amamentação 
Se está grávida ou a amamentar, se pensa estar grávida ou planeia engravidar, consulte o seu médico 
antes de tomar este medicamento. Deve fazê-lo porque não se sabe de que forma o medicamento irá 
afetar o bebé. </p>
<p>Condução de veículos e utilização de máquinas 
Não se prevê que SOTYKTU afete a sua capacidade de conduzir e utilizar máquinas. </p>
<p>SOTYKTU contém lactose 
Se foi informado pelo seu médico que tem intolerância a alguns açúcares, contacte-o antes de tomar 
este medicamento. </p>
<p>SOTYKTU contém sódio 
Este medicamento contém menos do que 1 mmol (23 mg) de sódio por comprimido, ou seja, é 
praticamente “isento de sódio". </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. Como tomar sotyktu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Como tomar sotyktu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tome este medicamento exatamente como indicado pelo seu médico ou farmacêutico. Fale com o seu 
médico ou farmacêutico se tiver dúvidas. </p>
<p>A dose recomendada é de 6 mg, tomada todos os dias. O comprimido deve ser engolido inteiro e pode 
ser tomado com ou sem alimentos. Não esmague, parta ou mastigue os comprimidos. </p>
<p>O seu médico decidirá durante quanto tempo tem de tomar SOTYKTU. </p>
<p>Se a sua condição não tiver melhorado após seis meses de tratamento, fale com o seu médico. </p>
<p>Se tomar mais SOTYKTU do que deveria 
Se tiver tomado mais SOTYKTU do que deveria, fale com o seu médico assim que possível. Poderá 
ter alguns dos efeitos indesejáveis listados na secção 4.<br />
Caso se tenha esquecido de tomar SOTYKTU 
Caso se tenha esquecido de tomar SOTYKTU, tome a dose normal no dia seguinte. Não tome uma 
dose a dobrar para compensar um comprimido que se esqueceu de tomar. </p>
<p>Se parar de tomar SOTYKTU 
Não pare de tomar SOTYKTU sem falar com o seu médico primeiro. Se parar o tratamento, os 
sintomas da psoríase podem voltar. </p>
<p>Caso ainda tenha dúvidas sobre a utilização deste medicamento, fale com o seu médico ou 
farmacêutico. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Efeitos indesejáveis possíveis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Efeitos indesejáveis possíveis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Como todos os medicamentos, este medicamento pode causar efeitos indesejáveis, embora estes não 
se manifestem em todas as pessoas. </p>
<p>Muito frequentes (podem afetar mais de 1 em 10 pessoas) </p>
<ul>
<li>infeções das vias respiratórias superiores (nariz e garganta) com sintomas como dor de garganta 
e nariz entupido </li>
</ul>
<p>Frequentes (podem afetar até 1 em 10 pessoas) </p>
<ul>
<li>
<p>infeção viral na boca (tal como herpes labial) </p>
</li>
<li>
<p>aumento do nível de uma enzima no sangue denominada creatina fosfoquinase (CPK) </p>
</li>
<li>
<p>feridas na boca </p>
</li>
<li>
<p>erupções cutâneas tipo acne </p>
</li>
<li>
<p>inflamação dos folículos pilosos </p>
</li>
</ul>
<p>Pouco frequentes (podem afetar até 1 em 100 pessoas) </p>
<ul>
<li>zona (herpes zoster) </li>
</ul>
<p>Comunicação de efeitos indesejáveis 
Se tiver quaisquer efeitos indesejáveis, incluindo possíveis efeitos indesejáveis não indicados neste 
folheto, fale com o seu médico, farmacêutico ou enfermeiro. Também poderá comunicar efeitos 
indesejáveis diretamente através do sistema nacional de notificação mencionado no Apêndice V. Ao 
comunicar efeitos indesejáveis, estará a ajudar a fornecer mais informações sobre a segurança deste 
medicamento. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. Como conservar sotyktu"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Como conservar sotyktu"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Manter este medicamento fora da vista e do alcance das crianças. </p>
<p>Não utilize este medicamento após o prazo de validade impresso no blister e na embalagem exterior, 
após “EXP". O prazo de validade corresponde ao último dia do mês indicado. </p>
<p>O medicamento não necessita de quaisquer precauções especiais de conservação. </p>
<p>Não utilize este medicamento se verificar que os comprimidos estão danificados ou que existem sinais 
de adulteração da embalagem do medicamento. </p>
<p>Não deite fora quaisquer medicamentos na canalização ou no lixo doméstico. Pergunte ao seu 
farmacêutico como deitar fora os medicamentos que já não utiliza. Estas medidas ajudarão a proteger 
o ambiente. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Conteúdo da embalagem e outras informações"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Conteúdo da embalagem e outras informações"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Qual a composição de SOTYKTU 
A substância ativa é o deucravacitinib. Cada comprimido revestido por película contém 6 mg de 
deucravacitinib. </p>
<p>Os outros componentes são </p>
<ul>
<li>
<p>núcleo do comprimido: acetato succinato de hipromelose, lactose anidra, celulose 
microcristalina, croscarmelose sódica, sílica coloidal hidratada e estearato de magnésio. </p>
</li>
<li>
<p>película de revestimento: álcool polivinílico, dióxido de titânio (E171), macrogol, talco, óxido 
de ferro vermelho (E172) e óxido de ferro amarelo (E172). </p>
</li>
</ul>
<p>Qual o aspeto de SOTYKTU e conteúdo da embalagem 
SOTYKTU é um comprimido revestido por película redondo e biconvexo, cor-de-rosa, marcado com 
“BMS 895" e “6 mg" num dos lados em duas linhas, liso no outro lado. </p>
<p>Os comprimidos revestidos por película são fornecidos em blisters calendário ou não calendário com 7 
ou 14 comprimidos. 
Cada embalagem contém 7, 14, 28 ou 84 comprimidos revestidos por película. </p>
<p>É possível que não sejam comercializadas todas as apresentações. </p>
<p>Titular da Autorização de Introdução no Mercado 
Bristol-Myers Squibb Pharma EEIG 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIrlanda </p>
<p>Fabricante 
Swords Laboratories Unlimited Company 
T/A Bristol-Myers Squibb Pharmaceutical Operations 
External Manufacturing 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIrlanda </p>
<p>Para quaisquer informações sobre este medicamento, queira contactar o representante local do Titular 
da Autorização de Introdução no Mercado: </p>
<p>Belgique/België/Belgien 
N.V. Bristol-Myers Squibb Belgium S.A. 
Tél/Tel: + 32 2 352 76 medicalinfo.belgium@bms.com </p>
<p>Lietuva 
Swixx Biopharma UAB 
Tel: + 370 52 369medinfo.lithuania@swixxbiopharma.com </p>
<p>България 
Swixx Biopharma EOOD 
Teл.: + 359 2 4942 medinfo.bulgaria@swixxbiopharma.com </p>
<p>Luxembourg/Luxemburg 
N.V. Bristol-Myers Squibb Belgium S.A. 
Tél/Tel: + 32 2 352 76 medicalinfo.belgium@bms.com </p>
<p>Česká republika 
Bristol-Myers Squibb spol. s r.o. 
Tel: + 420 221 016 medinfo.czech@bms.com </p>
<p>Magyarország 
Bristol-Myers Squibb Kft. 
Tel.: + 36 1 301 9Medinfo.hungary@bms.com </p>
<p>Danmark 
Bristol-Myers Squibb Denmark 
Tlf: + 45 45 93 05 medinfo.denmark@bms.com </p>
<p>Malta 
A.M. Mangion Ltd 
Tel: + 356 23976pv@ammangion.com </p>
<p>Deutschland 
Bristol-Myers Squibb GmbH &amp; Co. KGaA 
Tel: 0800 0752002 (+ 49 89 121 42 350) 
medwiss.info@bms.com </p>
<p>Nederland 
Bristol-Myers Squibb B.V. 
Tel: + 31 (0)30 300 2medischeafdeling@bms.com </p>
<p>Eesti 
Swixx Biopharma OÜ 
Tel: + 372 640 1medinfo.estonia@swixxbiopharma.com </p>
<p>Norge 
Bristol-Myers Squibb Norway AS 
Tlf: + 47 67 55 53 medinfo.norway@bms.com </p>
<p>Ελλάδα 
Bristol-Myers Squibb A.E. 
Τηλ: + 30 210 6074medinfo.greece@bms.com </p>
<p>Österreich 
Bristol-Myers Squibb GesmbH 
Tel: + 43 1 60 14 medinfo.austria@bms.com </p>
<p>España 
Bristol-Myers Squibb, S.A. 
Tel: + 34 91 456 53 informacion.medica@bms.com </p>
<p>Polska 
Bristol-Myers Squibb Polska Sp. z o.o. 
Tel.: + 48 22 2606informacja.medyczna@bms.com </p>
<p>France 
Bristol-Myers Squibb SAS 
Tél: + 33 (0)1 58 83 84 infomed@bms.com </p>
<p>Portugal 
Bristol-Myers Squibb Farmacêutica Portuguesa, 
S.A. 
Tel: + 351 21 440 70 portugal.medinfo@bms.com </p>
<p>Hrvatska 
Swixx Biopharma d.o.o. 
Tel: + 385 1 2078 medinfo.croatia@swixxbiopharma.com </p>
<p>România 
Bristol-Myers Squibb Marketing Services S.R.L. 
Tel: + 40 (0)21 272 16 medinfo.romania@bms.com </p>
<p>Ireland 
Bristol-Myers Squibb Pharmaceuticals uc 
Tel: 1 800 749 749 (+ 353 (0)1 483 3625) 
medical.information@bms.com </p>
<p>Slovenija 
Swixx Biopharma d.o.o. 
Tel: + 386 1 2355 medinfo.slovenia@swixxbiopharma.com </p>
<p>Ísland 
Vistor hf. 
Sími: + 354 535 7vistor@vistor.is 
medical.information@bms.com </p>
<p>Slovenská republika 
Swixx Biopharma s.r.o. 
Tel: + 421 2 20833 medinfo.slovakia@swixxbiopharma.com<br />
Italia 
Bristol-Myers Squibb S.r.l. 
Tel: + 39 06 50 39 medicalinformation.italia@bms.com </p>
<p>Suomi/Finland 
Oy Bristol-Myers Squibb (Finland) Ab 
Puh/Tel: + 358 9 251 21 medinfo.finland@bms.com </p>
<p>Κύπρος 
Bristol-Myers Squibb A.E. 
Τηλ:  800 92666 (+ 30 210 6074300) 
medinfo.greece@bms.com </p>
<p>Sverige 
Bristol-Myers Squibb Aktiebolag 
Tel: + 46 8 704 71 medinfo.sweden@bms.com </p>
<p>Latvija 
Swixx Biopharma SIA 
Tel: + 371 66164medinfo.latvia@swixxbiopharma.com </p>
<p>United Kingdom (Northern Ireland) 
Bristol-Myers Squibb Pharmaceutical Limited 
Tel: +44 (0)800 731 1medical.information@bms.com </p>
<p>Este folheto foi revisto pela última vez em </p>
<p>Outras fontes de informação </p>
<p>Está disponível informação pormenorizada sobre este medicamento no sítio da internet da Agência </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-8ff5d67e0b7de732bda1082340f24212
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sotyktu Package Leaflet for language en"
Description: "ePI document Bundle for sotyktu Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-8ff5d67e0b7de732bda1082340f24212"
* entry[0].resource = composition-en-8ff5d67e0b7de732bda1082340f24212

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8ff5d67e0b7de732bda1082340f24212"
* entry[=].resource = mp8ff5d67e0b7de732bda1082340f24212
                            
                    
Instance: bundlepackageleaflet-da-8ff5d67e0b7de732bda1082340f24212
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sotyktu Package Leaflet for language da"
Description: "ePI document Bundle for sotyktu Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-8ff5d67e0b7de732bda1082340f24212"
* entry[0].resource = composition-da-8ff5d67e0b7de732bda1082340f24212

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8ff5d67e0b7de732bda1082340f24212"
* entry[=].resource = mp8ff5d67e0b7de732bda1082340f24212
                            
                    
Instance: bundlepackageleaflet-pt-8ff5d67e0b7de732bda1082340f24212
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sotyktu Package Leaflet for language pt"
Description: "ePI document Bundle for sotyktu Package Leaflet for language pt"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #pt

// Composition
* entry[0].fullUrl = "Composition/composition-pt-8ff5d67e0b7de732bda1082340f24212"
* entry[0].resource = composition-pt-8ff5d67e0b7de732bda1082340f24212

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8ff5d67e0b7de732bda1082340f24212"
* entry[=].resource = mp8ff5d67e0b7de732bda1082340f24212
                            
                    



Instance: mp8ff5d67e0b7de732bda1082340f24212
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product SOTYKTU 6 mg film-coated tablets"
Description: "SOTYKTU 6 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/23/1718/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "SOTYKTU 6 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 8ff5d67e0b7de732bda1082340f24212ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "sotyktu"

* status = #current
* mode = #working

* title = "List of all ePIs associated with sotyktu"

* subject = Reference(mp8ff5d67e0b7de732bda1082340f24212)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#sotyktu "sotyktu"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-8ff5d67e0b7de732bda1082340f24212) // sotyktu en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-8ff5d67e0b7de732bda1082340f24212) // sotyktu da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-pt-8ff5d67e0b7de732bda1082340f24212) // sotyktu pt
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "pt"




Instance: List-8ff5d67e0b7de732bda1082340f24212
InstanceOf: List

* insert 8ff5d67e0b7de732bda1082340f24212ListRuleset
    